[1]张 昊,马金连,孙兴伟,等.子宫动脉栓塞治疗子宫腺肌症疗效评估及预测因素分析[J].介入放射学杂志,2025,34(07):766-771.[doi:10.3969/j.issn.1008-794X.2025.07.015]
　ZHANG Hao,MA Jinlian,SUN Xingwei,et al.Uterine artery embolization for adenomyosis:evaluation of efficacy and analysis of predictive factors[J].J Intervent Med,2025,34(07):766-771.[doi:10.3969/j.issn.1008-794X.2025.07.015]
点击复制

子宫动脉栓塞治疗子宫腺肌症疗效评估及预测因素分析()

PDF下载中关闭

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
34
期数:
2025年07
页码:
766-771
栏目:
临床研究
出版日期:
2025-07-25

文章信息/Info

Title:
Uterine artery embolization for adenomyosis:evaluation of efficacy and analysis of predictive factors
文章编号:
1008-794X(2025)-007-0766-06
作者:
张 昊;  马金连;  孙兴伟;  王明瑶;  靳 勇
215004 江苏苏州 苏州大学附属第二医院(张 昊、孙兴伟、王明瑶、靳 勇); 南京中医药大学附属江阴医院(马金连)
Author(s):
ZHANG Hao; MA Jinlian; SUN Xingwei; WANG Mingyao; JIN Yong.
The Second Affiliated Hospital of Soochow University,Suzhou,Jiangsu Province 215004,China
关键词:
子宫动脉栓塞术;  子宫腺肌症;  疗效;  预测因素
分类号:
R711.74
DOI:
10.3969/j.issn.1008-794X.2025.07.015
文献标志码:
B
摘要:
目的 评估子宫动脉栓塞治疗子宫腺肌症(adenomyosis,AM)的疗效,并探讨其疗效预测因素。方法 回顾性分析2020年1月至2022年8月在苏州大学附属第二医院接受子宫动脉栓塞治疗的44例AM患者的病历资料,从MRI表现、血CA125水平以及痛经评分随访等,探讨子宫动脉栓塞治疗AM疗效预测因素。结果 44例AM患者均接受1次子宫动脉栓塞治疗,术后12个月MRI随访显示,子宫体积由术前(299.60±182.42)cm3降至术后(173.14±104.00)cm3,缩小36.64%(P<0.05),患者痛经评分从(7.70±2.60)分降至(2.20±2.37)分,痛经缓解率达88.64%(P<0.05),且无严重不良反应发生。增强MRI显示30例患者(68.18%)的病灶表现为完全坏死,术前病灶完全坏死患者的血清CA125水平(101.97±60.30)、表观扩散系数(apparent diffusion coefficient,ADC)值(1.012±0.271),明显低于病灶不完全坏死患者(P<0.05); 术前病灶完全坏死患者的T2信号比(T2SR)值(0.582±0.198)明显高于病灶不完全坏死患者(P<0.05)。根据ROC曲线结果分析,术前CA125的曲线下面积、灵敏度、特异度分别是0.844、60%、80%,术前ADC值的曲线下面积、灵敏度、特异度分别是0.760、80%、65%,术前T2SR值的曲线下面积、灵敏度、特异度分别是0.760、80%、70%,并显示ADC<1.116×10-3 mm2/s、T2SR>0.479、CA125<109.10可以作为子宫动脉栓塞治疗AM疗效的有力预测因素。结论 子宫动脉栓塞治疗AM能有效缓解患者痛经症状,且安全有效,ADC、T2SR、CA125可以作为子宫动脉栓塞治疗AM疗效的有力预测因素,对于预测病灶反应具有重要价值,有助于为患者治疗方案的选择提供参考。

参考文献/References:

[1] Li Q,Ding Y,Zhang XY,et al.Drug therapy for adenomyosis:a prospective,nonrandomized,parallel-controlled study[J].J Int Med Res,2018,46:1855-1865.
[2]Koninckx PR,Ussia A,Adamyan L,et al.The epidemiology of endometriosis is poorly known as the pathophysiology and diagnosis are unclear[J].Best Pract Res Clin Obstet Gynaecol,2021,71:14-26.
[3]Ozen M,Patel R,Hoffman M,et al.Update on endovascular therapy for fibroids and adenomyosis[J].Semin Intervent Radiol,2023,40:327-334.
[4]张 鹏,张 鹤,张国福.子宫腺肌病介入治疗进展[J].介入放射学杂志,2015,24:738-741.
[5]Kim MD,Kim YM,Kim HC,et al.Uterine artery embolization for symptomatic adenomyosis:a new technical development of the 1-2-3 protocol and predictive factors of MR imaging affecting outcomes[J].J Vasc Interv Radiol,2011,22:497-502.
[6]Kitamura Y,Allison SJ,Jha RC,et al.MRI of adenomyosis:changes with uterine artery embolization[J].AJR Am J Roentgenol,2006,186:855-864.
[7]Kroencke TJ,Scheurig C,Poellinger A,et al.Uterine artery embolization for leiomyomas:percentage of infarction predicts clinical outcome[J].Radiology,2010,255:834-841.
[8]Kobayashi H,Matsubara S.A classification proposal for adenomyosis based on magnetic resonance imaging[J].Gynecol Obstet Invest,2020,85:118-126.
[9]Kishi Y,Suginami H,Kuramori R,et al.Four subtypes of adenomyosis assessed by magnetic resonance imaging and their specification[J].Am J Obstet Gynecol,2012,207:111-114.
[10]Ananthakrishnan G,Macnaught G,Hinksman L,et al.Diffusion-weighted imaging in uterine artery embolisation:do findings correlate with contrast enhancement and volume reduction?[J].Br J Radiol,2012,85:e1046-e1050.
[11]Zheng R,Zeng D,Wan TT,et al.Predisposing factors for predicting the therapeutic response of adenomyosis after uterine artery embolization:serum CA125 levels and accompanying endometriosis[J].Diagn Interv Radiol,2018,24:364-371.
[12]王海波,李 刚,陈清亮,等.早期剖宫产瘢痕妊娠子宫动脉栓塞后清宫术中大出血发生及其影响因素[J].介入放射学杂志,2023,32:436-440.
[13]Wang S,Meng X,Dong Y.The evaluation of uterine artery embolization as a nonsurgical treatment option for adenomyosis[J].Int J Gynaecol Obstet,2016,133:202-205.
[14]Ma J,Brown B,Liang E.Long-term durability of uterine artery embolisation for treatment of symptomatic adenomyosis[J].Aust N Z J Obstet Gynaecol,2021,61:290-296.
[15]de Bruijn AM,Smink M,Lohle P,et al.Uterine artery embolization for the treatment of adenomyosis:a systematic review and meta-analysis[J].J Vasc Interv Radiol,2017,28:1629-1642.
[16]Charkhchi P,Cybulski C,Gronwald J,et al.CA125 and ovarian cancer:a comprehensive review[J].Cancers(Basel),2020,12:3730.
[17]Kil K,Chung JE,Pak HJ,et al.Usefulness of CA125 in the differential diagnosis of uterine adenomyosis and myoma[J].Eur J Obstet Gynecol Reprod Biol,2015,185:131-135.
[18]Tang Y,Wen MB,Xiang RM,et al.Serum CA125 as a biomarker for dysmenorrhea in adenomyosis[J].Int J Gynaecol Obstet,2023,163:131-139.
[19]Yu W,Liu G,Liu C,et al.Recurrence-associated factors of laparoscopic adenomyomectomy for severely symptomatic adenomyoma[J].Oncol Lett,2018,16:3430-3438.
[20]Liu S,Peng C,Wang Z,et al.Association of normalization of postoperative carbohydrate antigen 125 levels with treatment failure following uterine artery embolization for adenomyosis[J].J Obstet Gynaecol Res,2023,49:2753-2760.
[21]Moldassarina RS.Modern view on the diagnostics and treatment of adenomyosis[J].Arch Gynecol Obstet,2023,308:171-181.
[22]Bae SH,Kim MD,Kim GM,et al.Uterine artery embolization for adenomyosis:percentage of necrosis predicts midterm clinical recurrence[J].J Vasc Interv Radiol,2015,26:1290-1296.
[23]Hecht EM,Do K,Kang SK,et al.Diffusion-weighted imaging for prediction of volumetric response of leiomyomas following uterine artery embolization:a preliminary study[J].J Magn Reson Imaging,2011,33:641-646.
[24]Jung DC,Kim MD,Oh YT,et al.Prediction of early response to uterine arterial embolisation of adenomyosis:value of T2 signal intensity ratio of adenomyosis[J].Eur Radiol,2012,22:2044-2049.
[25]Jha RC,Zanello PA,Ascher SM,et al.Diffusion-weighted imaging(DWI)of adenomyosis and fibroids of the uterus[J].Abdom Imaging,2014,39:562-569.
[26]Park Y,Kim MD,Jung DC,et al.Can measurement of apparent diffusion coefficient before treatment predict the response to uterine artery embolization for adenomyosis?[J].Eur Radiol,2015,25:1303-1309.
(收稿日期:2024-06-12)
(本文编辑:茹 实)

相似文献/References:

[1]李忠学,周锦红,孙松,等.子宫动脉栓塞术在中晚期妊娠前置胎盘出血引产中的应用[J].介入放射学杂志,2008,(07):486.
　LI Zhongxue,ZHOU Jinhong,SUN Song,et al.Clinical applicatiaon of uterine arterial embolization for treatment of placenta praevia with hemorrhage in advanced stage of pregnancy[J].J Intervent Med,2008,(07):486.
[2]艾志刚,杨彦粉,管洁.子宫动脉栓塞治疗子宫腺肌病８０例疗效分析[J].介入放射学杂志,2010,(04):325.
　AI Zigang,YANG Yanfen,GUAN Jie.Uterine arterial embolization for the treatment of adenomyosis：an analysis of therapeutic results in８０cases[J].J Intervent Med,2010,(07):325.
[3]刘兆玉,单明,卢再鸣,等.子宫动脉栓塞治疗子宫肌瘤的生命质量观察[J].介入放射学杂志,2007,(04):240.
　LIU Zhao-yu,SHAN Ming,LU Zai-ming,et al.Evaluation of life quality after arterial uterine embolization for leiomyoma[J].J Intervent Med,2007,(07):240.
[4]张国福,尚鸣异,田晓梅,等.子宫动脉化疗栓塞术在子宫颈内妊娠中的应用[J].介入放射学杂志,2009,(03):182.
　ZHANG Guofu,SHANG Mingyi,TIAN Xiaomei,et al.Uterine artery chemoembolization：its application in treating cervical pregnancy[J].J Intervent Med,2009,(07):182.
[5]潘素招,卢爱金,王雪贞.１６例中期妊娠前置胎盘状态介入治疗的护理[J].介入放射学杂志,2009,(06):477.
　PAN Su-zhao,LU Ai-jin,WANG Xue-zhen.Nursing care for patients with placenta previa undergoing interventional therapy in the second trimester of pregnancy[J].J Intervent Med,2009,(07):477.
[6]花村,周广德,滕君,等.碘油平阳霉素乳剂联合利多卡因浸泡明胶海绵栓塞治疗子宫肌瘤的临床观察[J].介入放射学杂志,2008,(03):215.
　HUA Cun,ZHOU Guangde,TENG Jun,et al.Clinical observation of pingyangmycin，lidocaine，iodipin emulsion and absorbable gelatine sponge granules embolization treatment for hysteromyoma[J].J Intervent Med,2008,(07):215.
[7]沈亚伟,刘 凯,吕 军.术前中性粒细胞/淋巴细胞比值、血小板/淋巴细胞比值对UAE患者术后疼痛的预测价值[J].介入放射学杂志,2023,32(10):992.
　SHEN Yawei,LIU Kai,LV Jun..Predictive value of preoperative NLR and PLR for postoperative pain degree in patients receiving uterine artery embolization[J].J Intervent Med,2023,32(07):992.
[8]石静,谢军,李琳娜,等.不同性质球囊髂内动脉阻断术在凶险性前置胎盘剖宫产中的对比研究[J].介入放射学杂志,2024,33(09):1009.
　SHI Jing,XIE Jun,LI Linna,et al.Internal iliac artery block using balloon of different properties in cesarean section for delivery female patients with pernicious placenta previa：a comparative study[J].J Intervent Med,2024,33(07):1009.

备注/Memo

备注/Memo:
通信作者: 靳 勇 E-mail:jinyong@suda.edu.cn
更新日期/Last Update: 2025-07-25